Creation of ApoC-II Mutant Mice and Correction of their Hypertriglyceridemia with an ApoC-II Mimetic Peptide

Toshihiro Sakurai, Akiko Sakurai, Boris L. Vaisman, Marcelo J. Amar, Chengyu Liu, Scott M. Gordon, Steven K. Drake, Milton Pryor, Maureen L. Sampson, Lita A. Freeman, Ling Yang, and Alan T. Remaley

Journal of Pharmacology and Experimental Therapeutics



Supplemental Figure 1. Distribution of lipids in plasma separated by FPLC. 250 μL of plasma obtained from a heterozygous mouse was separated by FPLC. The level of TC and PL in the fractions was measured by enzymatic assay. Fractions of VLDL/Chylos (Elution volume: 14.0-17.0 mL), IDL (17.5-22.0 mL), LDL (22.5-26.0 mL), HDL (26.5-32.0 mL) or Albumin (32.5-38.0 mL) were pooled and lipoproteins were isolated from pooled fractions using LRA. Each sample was used for immunoblotting to detect apoC-II protein (Fig. 2B).